Literature DB >> 26407763

Age-specific localization of NMDA receptors on oligodendrocytes dictates axon function recovery after ischemia.

Selva Baltan1.   

Abstract

Oligodendrocytes and axons are the main targets of an ischemic white matter injury and the resultant loss of axon function underlies the clinical disability in patients who survive a stroke. The cellular mechanisms of ischemic injury change as a function of age in concordance with age-mediated structural changes in white matter. Shorter periods of injury cause rapid and robust loss of axon function together with widespread oligodendrocyte death. While blockade of NMDA receptors fails to benefit axon function, removal of extracellular Ca2+ during ischemia remarkably promotes axon function recovery in young white matter. However, these same approaches hinder axon function recovery and fail to protect oligodendrocytes in aging white matter. The obligatory GluN1 subunit of the NMDA receptor exhibits an age-specific expression pattern such that in young adult white matter, it is mostly localized on oligodendrocyte cell bodies, while in aging white matter, it is also observed on myelin processes. This age-dependent re-localization and redistribution pattern mimics GluN1 expression observed during development, but in reverse order. During development, GluN1 immunoreactivity traffics from astrocytes at postnatal day 4-11 (P4-11) to myelin processes at P12-18 and to oligodendrocytes cell bodies at P19-21. Although immature axons are more resistant to ischemia, blockade of NMDA receptors during ischemia at P4-11 and P12-18 worsens axon function recovery and fails to benefit axons at P19-21. Thus, age-specific expression patterns of NMDA receptor localization may seem to modulate the plasticity of oligodendrocytes and myelin in response to ischemia as a function of age in white matter. This article is part of the Special Issue entitled 'Oligodendrocytes in Health and Disease'.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axon function; Ca(2+); Compound action potential; Development; Electrophysiology; Myelin; Optic nerve

Mesh:

Substances:

Year:  2015        PMID: 26407763      PMCID: PMC4808487          DOI: 10.1016/j.neuropharm.2015.09.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

1.  NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia.

Authors:  I Micu; Q Jiang; E Coderre; A Ridsdale; L Zhang; J Woulfe; X Yin; B D Trapp; J E McRory; R Rehak; G W Zamponi; W Wang; P K Stys
Journal:  Nature       Date:  2005-12-21       Impact factor: 49.962

2.  NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury.

Authors:  Michael G Salter; Robert Fern
Journal:  Nature       Date:  2005-12-22       Impact factor: 49.962

3.  Age-related changes in cyclic GMP and PKG-stimulated cerebellar Na,K-ATPase activity.

Authors:  Cristoforo Scavone; Carolina Demarchi Munhoz; Elisa Mitiko Kawamoto; Isaias Glezer; Larissa de Sá Lima; Tania Marcourakis; Regina Pekelmann Markus
Journal:  Neurobiol Aging       Date:  2005-06       Impact factor: 4.673

4.  Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.

Authors:  T Ishii; K Moriyoshi; H Sugihara; K Sakurada; H Kadotani; M Yokoi; C Akazawa; R Shigemoto; N Mizuno; M Masu
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

5.  Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake.

Authors:  M Szatkowski; B Barbour; D Attwell
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

6.  A universal scaling law between gray matter and white matter of cerebral cortex.

Authors:  K Zhang; T J Sejnowski
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Role of RyRs and IP3 receptors after traumatic injury to spinal cord white matter.

Authors:  W E Thorell; L G Leibrock; S K Agrawal
Journal:  J Neurotrauma       Date:  2002-03       Impact factor: 5.269

8.  Brain development and aging: overlapping and unique patterns of change.

Authors:  Christian K Tamnes; Kristine B Walhovd; Anders M Dale; Ylva Østby; Håkon Grydeland; George Richardson; Lars T Westlye; J Cooper Roddey; Donald J Hagler; Paulina Due-Tønnessen; Dominic Holland; Anders M Fjell
Journal:  Neuroimage       Date:  2012-12-12       Impact factor: 6.556

Review 9.  Axon-glial signaling and the glial support of axon function.

Authors:  Klaus-Armin Nave; Bruce D Trapp
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

10.  NMDA receptor function, memory, and brain aging.

Authors:  J W Newcomer; N B Farber; J W Olney
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

View more
  11 in total

Review 1.  Glutamate and ATP at the Interface Between Signaling and Metabolism in Astroglia: Examples from Pathology.

Authors:  Vladimir Parpura; Elizabeth S Fisher; James D Lechleiter; Arne Schousboe; Helle S Waagepetersen; Sylvain Brunet; Selva Baltan; Alexei Verkhratsky
Journal:  Neurochem Res       Date:  2016-02-25       Impact factor: 3.996

2.  Preserving Mitochondrial Structure and Motility Promotes Recovery of White Matter After Ischemia.

Authors:  Chinthasagar Bastian; Jerica Day; Stephen Politano; John Quinn; Sylvain Brunet; Selva Baltan
Journal:  Neuromolecular Med       Date:  2019-05-31       Impact factor: 3.843

3.  Age-Related Changes in Axonal and Mitochondrial Ultrastructure and Function in White Matter.

Authors:  Katharine E Stahon; Chinthasagar Bastian; Shelby Griffith; Grahame J Kidd; Sylvain Brunet; Selva Baltan
Journal:  J Neurosci       Date:  2016-09-28       Impact factor: 6.167

4.  NOS3 Inhibition Confers Post-Ischemic Protection to Young and Aging White Matter Integrity by Conserving Mitochondrial Dynamics and Miro-2 Levels.

Authors:  Chinthasagar Bastian; Jane Zaleski; Katharine Stahon; Brandon Parr; Andrew McCray; Jerica Day; Sylvain Brunet; Selva Baltan
Journal:  J Neurosci       Date:  2018-06-11       Impact factor: 6.167

5.  CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways.

Authors:  Chinthasagar Bastian; John Quinn; Ajai Tripathi; Danielle Aquila; Andrew McCray; Ranjan Dutta; Selva Baltan; Sylvain Brunet
Journal:  Neurobiol Dis       Date:  2018-06-23       Impact factor: 7.046

6.  Increased ER Stress After Experimental Ischemic Optic Neuropathy and Improved RGC and Oligodendrocyte Survival After Treatment With Chemical Chaperon.

Authors:  Varun Kumar; Louise Alessandra Mesentier-Louro; Angela Jinsook Oh; Kathleen Heng; Mohammad Ali Shariati; Haoliang Huang; Yang Hu; Yaping Joyce Liao
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

7.  Identification of miRNAs That Mediate Protective Functions of Anti-Cancer Drugs During White Matter Ischemic Injury.

Authors:  Selva Baltan; Ursula S Sandau; Sylvain Brunet; Chinthasagar Bastian; Ajai Tripathi; Hung Nguyen; Helen Liu; Julie A Saugstad; Yalda Zarnegarnia; Ranjan Dutta
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 5.200

Review 8.  The effect of age-related risk factors and comorbidities on white matter injury and repair after ischemic stroke.

Authors:  Mingyue Xu; Michael M Wang; Yanqin Gao; Richard F Keep; Yejie Shi
Journal:  Neurobiol Dis       Date:  2018-07-11       Impact factor: 5.996

9.  Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells.

Authors:  Denisa Belov Kirdajova; Jan Kriska; Jana Tureckova; Miroslava Anderova
Journal:  Front Cell Neurosci       Date:  2020-03-19       Impact factor: 5.505

10.  Transient Receptor Potential Ankyrin-1 (TRPA1) Block Protects against Loss of White Matter Function during Ischaemia in the Mouse Optic Nerve.

Authors:  Wendy Lajoso; Grace Flower; Vincenzo Giacco; Anjuli Kaul; Circe La Mache; Andra Brăban; Angela Roxas; Nicola B Hamilton
Journal:  Pharmaceuticals (Basel)       Date:  2021-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.